Practical therapeutic drug management in HIV-infected patients: Use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization

Journal of Clinical Pharmacology

Volumn 48, Issue 9, 2008, Pages 1081-1091

  Neely, Michael ^a,b   Jelliffe, Roger ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

Concentration control; Dose optimization; HIV

Indexed keywords

AMPRENAVIR PHOSPHATE; ATAZANAVIR; EFAVIRENZ; NELFINAVIR;

ADOLESCENT; ADULT; ARTICLE; BAYES THEOREM; CASE REPORT; COMPUTER PROGRAM; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MONITORING; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PATIENT; PHYSICIAN; POPULATION MODEL; RECOMMENDED DRUG DOSE; SOMNOLENCE; TREATMENT OUTCOME; VIRUS LOAD;

ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BAYES THEOREM; CHILD; COMPUTER SIMULATION; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; REVERSE TRANSCRIPTASE INHIBITORS; SOFTWARE;

EID: 49649115506     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008321789     Document Type: Article

References (59)

1. Fraaij PL, van Kampen JJ, Burger DM, de Groot R. Pharmacokinetics of antiretroviral therapy in HIV-1-infected children. Clin Pharmacokinet. 2005 ; 44 (9). 935-956.
2. Reed MD, Besunder JB Developmental pharmacology: ontogenic basis of drug disposition. Pediatr Clin North Am. 1989 ; 36 (5). 1053-1074.
3. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med. 2003 ; 349 (12). 1157-1167.
4. Lent-Evers NA, Mathot RA, Geus WP, van Hout BA, Vinks AA Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Monit. 1999 ; 21 (1). 63-73.
5. Bleyzac N., Souillet G., Magron P., et al. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant. 2001 ; 28 (8). 743-751.
6. Fletcher CV, Anderson PL, Kakuda TN, et al. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS. 2002 ; 16 (4). 551-560.
7. Best BM, Goicoechea M., Witt MD, et al. A randomized controlled trial of therapeutic drug monitoring in treatment-naive and -experienced HIV-1-infected patients. J Acquir Immune Defic Syndr. 2007 ; 46 (4). 433-442.
8. Boyd MA, Siangphoe U., Ruxrungtham K., et al. The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity. J Antimicrob Chemother. 2006 ; 57 (6). 1161-1167.
9. Burger D., Hugen P., Reiss P., et al. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS. 2003 ; 17 (8). 1157-1165.
10. Cleijsen RM, van de Ende ME, Kroon FP, et al. Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice. J Antimicrob Chemother. 2007 ; 60: 897-900.
11. Durant J., Clevenbergh P., Garraffo R., et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study. AIDS. 2000 ; 14: 1333-1339.
12. Wasmuth JC, Lambertz I., Voigt E., et al. Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity. Eur J Clin Pharmacol. 2007 ; 63: 901-908.
13. Fletcher CV, Brundage RC, Fenton T., et al. Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial. Clin Pharmacol Ther. 2008 ; 83 (2). 300-306.
14. Dahri K., Ensom MH Efavirenz and nevirapine in HIV-1 infection: is there a role for clinical pharmacokinetic monitoring ? Clin Pharmacokinet. 2007 ; 46: 109-132.
15. Fraaij PL, Rakhmanina N., Burger DM, de GR Therapeutic drug monitoring in children with HIV/AIDS. Ther Drug Monit. 2004 ; 26: 122-126.
16. Wertheimer BZ, Freedberg KA, Walensky RP, Yazdanapah Y., Losina E. Therapeutic drug monitoring in HIV treatment: a literature review. HIV Clin Trials. 2006 ; 7 (2). 59-69.
17. US Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. May 4, 2006. http://www.aidsinfonihgov. Accessed July 7, 2006.
18. Acosta EP, Gerber JG Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retroviruses. 2002 ; 18 (12). 825-834.
19. Acosta EP, King JR Methods for integration of pharmacokinetic and phenotypic information in the treatment of infection with human immunodeficiency virus. Clin Infect Dis. 2003 ; 36 (3). 373-377.
20. European AIDS Clinical Society (EACS). Guidelines for the Clinical Management and Treatment of HIV-Infected Adults in Europe. December 1, 2007. http://www.eacseu/guide/indexhtm. Accessed May 15, 2008.
21. Bossi P., Peytavin G., it- Mohand H., et al. GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. HIV Med. 2004 ; 5 (5). 352-359.
22. Clevenbergh P., Garraffo R., Durant J., Dellamonica P. PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results. AIDS. 2002 ; 16: 2311-2315.
23. Khoo SH, Lloyd J., Dalton M., et al. Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN)-a randomized controlled trial of therapeutic drug monitoring and adherence support. J Acquir Immune Defic Syndr. 2006 ; 41: 461-467.
24. Torti C., Quiros-Roldan E., Regazzi M.,, et al. RADAR-MASTER Study Group. A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study. Clin Infect Dis. 2005 ; 40 (12). 1828-1836.
25. Jelliffe R., Schumitzky A., Bayard D., Van Guilder M., Leary RH The USC*PACK programs for parametric and nonparametric population PK/PD modeling, for multiple model adaptive control of drug dosage regimens, and for IMM Bayesian posterior individual models with changing parameter distributions during the period of data analysis [abstract]. Population Analysis Group in Europe, Paris, France, June 2002.
26. Bayard DS, Jelliffe RW A Bayesian approach to tracking patients having changing pharmacokinetic parameters. J Pharmacokinet Pharmacodyn. 2004 ; 31 (1). 75-107.
27. Jelliffe R., Bayard D., Milman M., Van Guilder M., Schumitzky A. Achieving target goals most precisely using nonparametric compartmental models and "multiple model" design of dosage regimens. Ther Drug Monit. 2000 ; 22 (3). 346-353.
28. Ette EI, Williams PJ Population pharmacokinetics I: background, concepts, and models. Ann Pharmacother. 2004 ; 38 (10). 1702-1706.
29. Jelliffe RW, Maire P. Goal-oriented, model-based drug regimens. Comput Biol Med. 2001 ; 31 (3). 145-146.
30. Bayard D., Jelliffe R., Schumitzky A., Milman M., Van Guilder M. Precision drug dosage regimens using multiple model adaptive control: theory and application to simulated vancomycin therapy. In: Sridhar R, Rao KS, Lakshminarayanan V, eds. Selected Topics in Mathematical Physics, Prof. R. Vasudevan Memorial Volume. Madras, India: World Scientific Publishing ; 1995.
31. Neely MN, Lam J., Kovacs A., Van Guilder M., Jelliffe R., Louie S. Novel modeling strategy using random antiretroviral drug levels to measure adherence in HIV-infected patients. Abstract presented at: 7th Annual HIV Pharmacology Workshop ; 2006 ; Lisbon, Portugal.
32. Metropolis N., Ulam S. The Monte Carlo method. J Am Stat Assoc. 1949 ; 44 (247). 335-341.
33. Bustad A., Terziivanov D., Leary R., Port R., Schumitzky A., Jelliffe R. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies. Clin Pharmacokinet. 2006 ; 45 (4). 365-383.
34. Hirt D., Urien S., Jullien V., et al. Age-related effects on nelfinavir and M8 pharmacokinetics: a population study with 182 children. Antimicrob Agents Chemother. 2006 ; 50 (3). 910-916.
35. Csajka C., Marzolini C., Fattinger K., et al. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther. 2003 ; 73 (1). 20-30.
36. Starr SE, Fletcher CV, Spector SA, et al. Efavirenz liquid formulation in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2002 ; 21 (7). 659-663.
37. Kashuba AD, Tierney C., Downey GF, et al. Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. AIDS. 2005 ; 19 (2). 145-152.
38. Wire MB, Shelton MJ, Studenberg S. Fosamprenavir: clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet. 2006 ; 45 (2). 137-168.
39. Colombo S., Buclin T., Cavassini M., et al. Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother. 2006 ; 50 (11). 3801-3808.
40. Keil K., Hochreitter J., DiFrancesco R., et al. Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and application. Ther Drug Monit. 2007 ; 29: 103-109.
41. Holland DT, DiFrancesco R., Connor JD, Morse GD Quality assurance program for pharmacokinetic assay of antiretrovirals: ACTG proficiency testing for pediatric and adult pharmacology support laboratories, 2003 to 2004: a requirement for therapeutic drug monitoring. Ther Drug Monit. 2006 ; 28: 367-374.
42. Sustiva [prescribing information]. New York, NY: Bristol-Myers Squibb ; 2007. http://packageinsertsbmscom/pi/pi_sustivapdf. Accessed December 18, 2007.
43. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004 ; 18 (18). 2391-2400.
44. Kappelhoff BS, Crommentuyn KM, de Maat MM, Mulder JW, Huitema AD, Beijnen JH Practical guidelines to interpret plasma concentrations of antiretroviral drugs. Clin Pharmacokinet. 2004 ; 43 (13). 845-853.
45. Viracept [prescribing information]. New York, NY: Pfizer ; 2007. www.PfizerPro.com/Viracept. Accessed December 18, 2007.
46. Gonzalez de Requena D., Bonora S., Canta F., et al. Atazanavir Ctrough is associated with efficacy and safety: definition of therapeutic range. Poster Abstracts, 12th Conference on Retroviruses and Opportunistic Infections ; 2005 ; Boston, MA.
47. Saitoh A., Sarles E., Capparelli E., et al. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS. 2007 ; 21: 2191-2199.
48. Gatanaga H., Hayashida T., Tsuchiya K., et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect Dis. 2007 ; 45: 1230-1237.
49. Burger D., van der Heiden I., la Porte C., et al. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol. 2006 ; 61 (2). 148-154.
50. US Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. February 28, 2008. http://www.aidsinfonihgov. Accessed March 6, 2008.
51. Nettles R., Kieffer T., Parsons T., et al. Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis. 2006 ; 42 (8). 1189-1196.
52. Haas D. Editorial commentary: can responses to antiretroviral therapy be improved by therapeutic drug monitoring? Clin Infect Dis. 2006 ; 42 (8). 1197-1199.
53. Neely MN, van den Anker J., Soldin SJ, Williams K., Baghdassarian A., Rakhmanina N. Population kinetics and dynamics of lopinavir in HIV-infected children. Abstract presented at: 17th Population Approach Group in Europe Meeting ; June 2008. Abstract 1340.
54. Neely MN, Jelliffe R. Population pharmacokinetic models and individualized Bayesian dose optimization in HIV patients. Abstract presented at: First American Conference on Pharmacometrics ; March 2008 ; Tucscon, AZ.
55. Drugs used in the treatment of HIV infection. January 2008. http://www.fdagov/oashi/aids/viralshtml. Accessed March 15, 2008.
56. Villani P., Floridia M., Pirillo MF, et al. Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women. Br J Clin Pharmacol. 2006 ; 62: 309-315.
57. Bryson YJ, Mirochnick M., Stek A., et al. Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353. HIV Clin Trials. 2008 ; 9: 115-125.
58. Stek AM, Mirochnick M., Capparelli E., et al. Reduced lopinavir exposure during pregnancy. AIDS. 2006 ; 20: 1931-1939. 59. Mirochnick M., Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet. 2004 ; 43 (15). 1071-1087.
59. Robertson SM, Penzak SR, Pau A. Drug interactions in the management of HIV infection: an update. Expert Opin Pharmacother. 2007 ; 8 (17). 2947-2963.